Cancer vaccines

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 366, Issue 1579, 2011, Pages 2823-2826

  Liu, Margaret A ^a  

^a ProTherImmune and Karolinska Institutet   (United States)

Author keywords

Human papilloma virus; Immunosurveillance; Immunotherapy; Malignancy

Indexed keywords

ANTIBODY; CANCER; DISEASE TREATMENT; ETIOLOGY; HEPATITIS; IMMUNIZATION; INFECTIOUS DISEASE; TUMOR; VACCINATION; VACCINE;

HUMAN PAPILLOMAVIRUS;

EID: 80052460917     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0101     Document Type: Review

References (27)

1. Schiller, J. T. & Lowy, D. R. 2004 Human papillomavirus vaccines for cervical cancer prevention. In Vaccines (eds S. A. Plotkin & W. A. Orenstein), pp. 1259-1265, 4th edn. Philadelphia, PA: Saunders.
2. Jansen, K. U. & Frazer, I. H. 2010 Vaccines against human papillomaviruses. In New generation vaccines (eds M. Levine, G. Dougan, M. F. Good, M. A. Liu, G. J. Nabel, J. P. Nataro & R. Rappuoli), pp. 954-961. 4th edn. New York, NY: Informa.
3. Parkin, D. M. & Bray, F. 2006 The burden of HPV related cancers. Vaccine 24, 11-25. (doi:10.1016/j.vaccine.2006.05.111)
4. Armstrong, E. P. 2010 Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J. Manag. Care Pharm. 16, 217-230.
5. Gutierrez-Dalmau, A. & Campistol, J. M. 2007 Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 67, 1167-1198. (doi:10.2165/00003495-200767080-00006)
6. Piazuelo, M. B., Epplein, M. & Correa, P. 2010 Gastric cancer: an infectious disease. Infect. Dis. Clin. North Am. 24, 853-869. (doi:10.1016/j.idc.2010.07.010)
7. Salim, O. E. H., Hamid, H. K. S., Mekki, S. O., Suleiman, S. H. & Ibrahim, S. Z. 2010 Colorectal carcinoma associated with schistosomiasis: a possible causal relationship. World J. Surg. Oncol. 8, 68. (doi:10. 1186/1477-7819-8-68)
8. Zanger, P., Habscheid, W., Kremsner, P. G. & Dahm, H. H. 2010 Schistosoma japonicum infection and rectal carcinoid tumour: underreported coincidence or neglected association? Epidemiol. Infect. 138, 1289-1291. (doi:10. 1017/S095026880999152X)
9. Sgambato, A. & Cittadini, A. 2010 Inflammation and cancer: a multifaceted link. Eur. Rev. Med. Pharmacol. Sci. 14, 263-268.
10. Burnet, M. 1957 Cancer: a biological approach. Br. Med. J. 1, 841-847. (doi:10.1136/bmj.1.5023.841)
11. Hurwitz, P. J. 1991 Spontaneous regression of metastatic melanoma. Ann. Plast. Surg. 26, 403-406. (doi:10.1097/00000637-199104000-00016)
12. Borshoff, C. & Weiss, R. 2002 AIDS-related malignancies. Nat. Rev. Cancer 2, 373-382. (doi:10.1038/nrc797)
13. Bonnet, F. & Chêne, G. 2008 Evolving epidemiology of malignancies in HIV. Curr. Opin. Oncol. 20, 534-540. (doi:10.1097/CCO.0b013e32830a5080)
14. Gutierrez-Dalmau, A. & Campistol, J. M. 2007 Immunosuppressive therapy and malignancy in organ transplant recipients. Drugs 67, 1167-1198. (doi:10. 2165/00003495-200767080-00006)
15. Shapi, R. S. 2011 Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am. J. Hematol. 86, 48-55. (doi:10.1002/ ajh.21903)
16. Eklund, J. W. & Kuzel, T. M. 2005 Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treat Res. 126, 263-287. (doi:10.1007/ 0-387-24361-5_11)
17. Higuchi, T., Shimizu, M., Owaki, A., Takahashi, M., Shinya, E., Nishimura, T. & Takahashi, H. 2009 A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate eVector cells for the inhibition of tumor growth. Cancer Immunol. Immunother. 58, 1245-1255. (doi:10.1007/s00262-008-0643-x)
18. Aldrich, J. F., Lowe, D. G., Shearer, M. H., Winn, R. E., Jumper, C. A.& Kennedy, R.C. 2010 Vaccines and immunotherapeutics for the treatment ofmalignant disease. Clin. Dev. Immunol. 2010, 697158. (doi:10.1155/2010/697158)
19. Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A. & George, A. J. T. 2010 The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325-338. (doi:10.1038/nrd3003)
20. Goldman, B. & DeFrancesco, L. 2009 The cancer vaccine roller coaster. Nat. Biotechnol. 27, 129-139. (doi:10.1038/nbt0209-129)
21. Kantoff, P. et al. 2010 Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422. (doi:10.1056/NEJMoa1001294)
22. Bergman, P. J. et al. 2003 Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin. Cancer Res. 9, 1284-1290.
23. Liao, J. C., Gregor, P., Wolchok, J. D., Orlandi, F., Craft, D., Leung, C., Houghton, A. N. & Bergman, P. J. 2006 Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 6, 8.
24. Beatson, R. E., Taylor-Papadimitriou, J. & Burchell, J. M. 2010 MUC1 immunotherapy. Immunotherapy 2, 305-327. (doi:10.2217/imt.10.17)
25. Pashov, A., Monzavi-Karbassi, B., Raghava, G. P. S. & Kieber-Emmons, T. 2010 Bridging innate and adaptive antitumor immunity targeting glycans. J. Biomed. Biotechnol. 2010, 354068. (doi:10.1155/2010/354068)
26. Malmberg, K.-J. & Ljunggren, G. 2006 Escape from immune- and nonimmune-mediated tumor surveillance. Semin. Cancer Biol. 16, 16-31. (doi:10.1016/j.semcancer. 2005.07.007)
27. Sengupta, N., MacFie, T. S., MacDonald, T. T., Pennington, D. & Silver, A. R. 2010 Cancer immunoediting and 'spontaneous' tumor regression. Pathol. Res. Pract. 206, 1-8. (doi:10.1016/j.prp.2009.10.001)